Printer Friendly
The Free Library
23,403,340 articles and books


Obliterative muscularization of the small bowel submucosa in crohn disease: a possible mechanism of small bowel obstruction.

Stricture formation in Crohn disease has been traditionally ascribed to fibrosis of the submucosa after ulceration. (1-3) In general, fibrosis of the muscularis propria was not a feature, but changes of the muscularis mucosa were noted. (1-4) Fibromuscular proliferation has been mentioned. (3,4) Shepherd and Jass (5) showed that the so-called neuromuscular and vascular hamartoma, characterized by extensive muscular proliferation and associated with small bowel strictures, is actually "burnt out" Crohn disease.

In reviewing resection specimens of Crohn disease from the ileum, we have noted an extensive proliferation of smooth muscle obliterating the submucosa. This observation was distinct from the usual thickening and splaying of the muscularis mucosa described in healed ulcerations/ The aim of our study was to examine whether this pathologic change, obliterative muscularization of the submucosa (OMUS), could be associated with the formation of small bowel strictures.

MATERIALS AND METHODS

We reviewed 50 ileal partial resections from adult patients with indisputable diagnosis of Crohn disease examined during 1995-2000. All the patients had advanced Crohn disease, with clinical manifestations present for several years. Features of small bowel obstruction had been recorded in the records of most of the patients. Seven patients had a history of recurrent episodes of intestinal obstruction. The patients had no history of previous surgery or anastomosis. All the resection specimens had been examined in the Department of Pathology of Indiana University Hospital, Indianapolis, following routine procedures. The histopathologic slides were reviewed initially without knowledge of the gross findings by 4 pathologists. Since thickening of the muscularis mucosa and muscularis propria as well as fibromuscular proliferation in the submucosa are not uncommon, OMUS was defined as a thick and continuous muscle layer from the mucosal base to the muscularis propria that was at least 1 cm in length and that lacked distinct bands of scarring. Subsequently, the macroscopic descriptions were reviewed, and the presence and location of OMUS were correlated with the presence and location of strictures. Statistical analysis was performed using the Fisher exact test.

Representative sections from each case showing muscularization of the submucosa were stained with the Gomori 1-step trichrome method without pretreatment of sections with hot Bouin solution.

In addition, representative sections from each case showing muscularization of the submucosa were analyzed immunohisto-chemically for smooth muscle-specific actin (monoclonal antibody 1A4, Dako Corporation, Carpinteria, Calif) and desmin (monoclonal antibody D33, Dako). A conventional avidin-biotin complex method was used with microwave antigen retrieval. Appropriate positive and negative control slides were stained in parallel.

RESULTS

Patients in this study included 30 females and 20 males (age 17-74 years; average, 37.7 years; median, 36.5 years). Obliterative muscularization of the submucosa was noted in 14 of the 50 ileal resections reviewed. It was characterized by submucosal muscle fibers organized in compact interlacing bundles, strongly reminiscent of a muscular layer of bowel wall, especially of a very thick muscularis mucosa (Figures 1-4). Indeed, in many cases distinction between muscularis mucosa and OMUS was not feasible. The muscularis propria could be distinguished from OMUS (Figures 1 and 2). As expected, OMUS showed strong immunostaining with antibodies to smooth muscle actin and desmin (Figure 5). A small amount of inflamed connective tissue was also seen in the region of OMUS. Adjacent sections taken from the area of the strictures showed submucosal fibrosis. Additional features of Crohn disease, such as fissuring ulcers, granulomas, lymphoid aggregates, and pseudopyloric metaplasia, were also noted in most of the cases. The mucosa overlying regions of OMUS was inflamed, focally ulcerated, and frequently showed prominent pseudopyloric metaplasia. In approximately 30% of the cases, histologic sections, obtained from regions close to OMUS, showed fissuring ulcers frequently associated with thickening and fusion of the muscularis mucosa and muscularis propria. Increased fistula formation was not seen in the vicinity of OMUS.

[FIGURES 1-5 OMITTED]

Obliterative muscularization of the submucosa was noted in 14 ileal resections, and in 11 of 14 it was detected in the sections obtained from the area of stricture. In the remaining 3 cases, the bowel wall was thick and rigid without grossly identifiable stricture. Correlation between the presence of OMUS and strictures is summarized in Figure 6. Small bowel strictures were by far more common in those specimens showing OMUS (11/14 vs 3/36). The difference was statistically significant (P < .001).

[FIGURE 6 OMITTED]

COMMENT

Obliterative muscularization of the submucosa resembles the neuromuscular and vascular hamartoma, considered by Shepherd and Jass (5) as part of the histologic spectrum of Crohn disease. Indeed, these authors mentioned that "we have recently reviewed 50 sequential cases of small intestinal Crohn's disease and histological features identical to those of neuromuscular and vascular hamartoma ... are not uncommon findings." (5) They indicated that "muscularization of the submucosa" can be seen also in ischemic and radiation enteritis. (5)

The mechanism of OMUS formation is not clear. Direct muscularization of fibrotic submucosa has been considered previously. (5) Alternatively, our findings suggest that OMUS could be the result of proliferation and fusion of reparative muscularis mucosae and muscularis propria in the vicinity of serpiginous or fissuring ulcers, an interpretation implying that OMUS could simply be an epiphenomenon.

Intestinal obstruction is an important feature in the natural history of Crohn disease. (6) Several pathogenetic mechanisms have been proposed. (6) Stricture with fibrostenotic narrowing is considered the main mechanism in advanced Crohn disease, and it is expressed clinically as chronic obstruction.(6) Intermittent obstruction can be seen in early stages of the disease, presumably as the result of edema and spasm. (6) Recurrent episodes of acute intestinal obstruction can be superimposed on a picture of chronic obstruction. (6) These episodes have been attributed to impaction of food or flare-ups of inflammation and spasm. (6)

All the explanations of the intermittent obstruction invoke a transient mechanism of stenosis, edema, or spasm. Obliterative muscularization of the submucosa could be a suitable pathologic substrate of a spasm-mediated transient stenosis. Indeed, OMUS was found in all 7 patients with intermittent intestinal obstruction in our series.

While the association of OMUS and spasm-induced intestinal obstruction is not more than tentative, the association of OMUS with small bowel strictures is certain. The nature of this association is not clear. Several hypotheses are possible. Obliterative muscularization of the submucosa could undergo a prolonged or intense spasm causing unresolving bowel constriction. If this were true, "eel in rigor mortis" could be more than a mere historical and graphic description of bowel involved by Crohn disease. (7) Alternatively, OMUS, by minimizing the vasoprotective role of normal submucosa, could cause ischemia contributing to bowel scarring. Finally, OMUS could be an epiphenomenon, simply an indicator of advanced Crohn disease with excessive repair. (8,9)

In a recent study, intestinal smooth muscle cells were recovered from intestine with Crohn disease and sustained in culture. (10) These cells showed amplified contractile activity, and they expressed increased gelsolin, an actin-binding protein. (10) These findings suggest a role for contractility in stricturing and obstruction, and the possibility that obstruction could reflect more diverse pathologic processes than mere scarring. The need for better understanding of stricture formation in Crohn disease is further indicated by the successful application of more conservative therapeutic approaches, including stricturoplasty, (11) and inhibition of tumor necrosis factor-alpha by using a chimeric monoclonal antibody. (12) Rapidly developing obstructive symptoms have been recently reported in a subgroup of patients receiving this medication. The pathologic changes included increased collagen deposition in muscularis mucosa, submucosa, and muscularis propria, as well as "variable increase of myofibroblasts/ smooth muscle cells" in the submucosa. (12)

References

(1.) Morson BC, Dawson IMP, Day DW, Jass JR, Price AB, Williams GT. Inflammatory disorders. In: Morson and Dawson's Gastrointestinal Pathology. 3rd ed. Oxford, England: Blackwell Scientific Publications; 1990:240-302.

(2). Ming SC, Goldman H. Ulcerative colitis and Crohn's disease. In: Pathology of the Gastrointestinal Tract. Philadelphia, Pa: WB Saunders Co; 1992:643-681.

(3.) Lewin KJ, Riddel RH, Weinstein WM. Crohn's disease. In: Gastrointestinal Pathology and Its Clinical Implications. New York, NY: Igaku-Shoin Medical Publishers; 1992:858-903.

(4.) Tanaka M, Riddell RH. The pathological diagnosis and differential diagnosis of Crohn's disease. Hepatogastroenterology. 1990;37:18-31.

(5.) Shepherd NA, Jass JR. Neuromuscular and vascular hamartoma of the small intestine: is it Crohn's disease? Gut. 1987;28:1663-1668.

(6.) Feldman M, Scharschmidt BF, Sleisinger MH. Crohn's disease. In: Slesinger and Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia, Pa: WB Saunders Co; 1998:1708-1734.

(7.) Dalziel TK. Chronic intestinal enteritis. Br Med J. 1913;2:1068-1069.

(8.) Kelly JK, Sutherland LR. The chronological sequence in the pathology of Crohn's disease. J Clin Gastroenterol. 1988;10:28-33.

(9.) Kelly JK, Siu TO. The strictures, sinuses, and fissures of Crohn's disease. J Clin Gastroenterol. 1986;8:594-598.

(10.) Ehrlich HP, Allison GM, Page MJ, Kolton WA, Graham M. Increased gelsolin expression and retarded collagen lattice contraction with smooth muscle cells from Crohn's diseased intestine. J Cell Physiol. 2000;182:303-309.

(11.) Tonelli F, Ficari F. Strictureplasty in Crohn's disease: surgical options. Dis Colon Rectum. 2000;43:920-926.

(12.) Sidham VB, Komorowski R, Asma Z, et al. Histomorphologic changes in patients presenting with obstruction secondary to Infliximab therapy in Crohn's disease [abstract 547]. Mod Pathol. 2001;14:95A.

Accepted for publication June 4, 2001.

From the Department of Pathology, School of Medicine, Indiana University, Indianapolis.

Reprints: George K. Koukoulis, MD, University Hospital, Department of Pathology, Room 3465, 550 N University Blvd, Indianapolis, IN 46202-5280 (e-mail: gkoukoul@iupui.edu).
COPYRIGHT 2001 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:Koukoulis, G.; Ke, Y.; Henley, J.D.; Cummings, O.W.
Publication:Archives of Pathology & Laboratory Medicine
Geographic Code:1USA
Date:Oct 1, 2001
Words:1559
Previous Article:Bcl-2, Bcl-x, and Bax Expression by immunohistochemistry in inclusion body myositis: a study of 27 cases.
Next Article:Expression of thyroid transcription factor-1 and other markers in sclerosing hemangioma of the lung.
Topics:



Related Articles
Nasal septal perforation: A rare extraintestinal manifestation of Crohn's disease.
Biologic Therapy Helps Fight Crohn's Disease.
Primary Epstein-Barr Virus--Associated Hodgkin Disease of the Ileum Complicating Crohn Disease.
Serologic markers in inflammatory bowel disease (IBD). (Cover Story).
New drug for Crohn's disease. (Colitis Club Quarterly).
Bilateral phakic cystoid macular edema associated with Crohn's disease.
Small bowel capsule endoscopy: a systematic review.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters